AA
NVO

Auxano Advisors’s Novo Nordisk NVO Stock Holding History

Auxano Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.45M Buy
71,867
+7,559
+12% +$325K 0.65% 26
2026
Q1 		$2.36M Buy
64,308
+14,404
+29% +$682K 0.47% 35
2025
Q4 		$2.54M Buy
49,904
+3,064
+7% +$157K 0.5% 29
2025
Q3 		$2.6M Buy
46,840
+5,578
+14% +$327K 0.55% 26
2025
Q2 		$2.85M Buy
41,262
+1,870
+5% +$127K 0.67% 23
2025
Q1 		$2.74M Buy
39,392
+8,949
+29% +$739K 0.72% 24
2024
Q4 		$2.62M Buy
30,443
+429
+1% +$46.4K 0.66% 23
2024
Q3 		$3.57M Sell
30,014
-13
-0% -$1.73K 0.93% 19
2024
Q2 		$4.29M Sell
30,027
-208
-0.7% -$27.6K 1.19% 18
2024
Q1 		$3.88M Buy
30,235
+587
+2% +$69.9K 1.13% 18
2023
Q4 		$3.07M Sell
29,648
-180
-0.6% -$17.8K 1.03% 20
2023
Q3 		$2.71M Sell
29,828
-23,442
-44% -$2.07M 1.11% 19
2023
Q2 		$4.24M Hold
53,270
– – 1.7% 14
2023
Q1 		$4.24M Sell
53,270
-2,322
-4% -$165K 1.7% 14
2022
Q4 		$3.76M Buy
55,592
+154
+0.3% +$9.03K 1.7% 14
2022
Q3 		$2.76M Buy
55,438
+3,970
+8% +$213K 1.27% 17
2022
Q2 		$2.87M Buy
51,468
+1,386
+3% +$76.9K 1.42% 17
2022
Q1 		$2.78M Buy
50,082
+272
+0.5% +$14K 1.18% 18
2021
Q4 		$2.79M Buy
49,810
+116
+0.2% +$6.28K 1.25% 19
2021
Q3 		$2.39M Sell
49,694
-904
-2% -$43.7K 1.07% 19
2021
Q2 		$2.12M Buy
50,598
+528
+1% +$20.5K 0.97% 20
2021
Q1 		$1.69M Buy
50,070
+1,428
+3% +$50.9K 1.04% 23
2020
Q4 		$1.7M Buy
48,642
+2,304
+5% +$79.6K 1.12% 19
2020
Q3 		$1.61M Buy
46,338
+2,466
+6% +$82.2K 1.24% 19
2020
Q2 		$1.44M Buy
43,872
+350
+0.8% +$11.2K 1.19% 21
2020
Q1 		$1.31M Buy
+43,522
New +$1.3M 1.19% 21

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Auxano Advisors's NVO Position: Q2 2026 in Review

Auxano Advisors increased its Novo Nordisk (NVO) stake by 12% in Q2 2026, buying an estimated $325K and bringing the position to 71,867 shares worth $3.45M. The position accounts for 0.65% of the portfolio, ranked #26.

Auxano Advisors first reported a position in NVO in Q1 2020 and has held it in 26 quarters since. The position peaked at $4.29M in Q2 2024. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Auxano Advisors held 71,867 shares of Novo Nordisk worth $3.45M as of Q2 2026.
  • Auxano Advisors bought 7,559 Novo Nordisk shares in Q2 2026, an estimated $325K.
  • Novo Nordisk made up 0.65% of Auxano Advisors's portfolio in Q2 2026, its #26 holding.
  • Auxano Advisors first reported a position in Novo Nordisk in Q1 2020 and has held it in 26 quarters since.
  • Auxano Advisors's Novo Nordisk position peaked at $4.29M in Q2 2024.
  • 1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Auxano Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.